Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant BTLA antibody

This Hamster Chimeric antibody specifically detects BTLA in WB, FACS, IP, Func and BP. It exhibits reactivity toward Mouse.
Catalog No. ABIN7072471

Quick Overview for Recombinant BTLA antibody (ABIN7072471)

Target

See all BTLA Antibodies
BTLA (B and T Lymphocyte Associated (BTLA))

Antibody Type

Recombinant Antibody

Reactivity

  • 80
  • 31
  • 2
  • 2
  • 2
  • 1
Mouse

Host

  • 45
  • 36
  • 10
  • 3
  • 1
  • 1
Hamster

Clonality

  • 52
  • 43
  • 1
Chimeric

Conjugate

  • 53
  • 6
  • 5
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This BTLA antibody is un-conjugated

Application

  • 48
  • 47
  • 30
  • 13
  • 13
  • 12
  • 11
  • 9
  • 7
  • 6
  • 3
  • 3
  • 2
  • 1
  • 1
Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP), Functional Studies (Func), Blocking Peptide (BP)

Clone

HMBT-6B2
  • Purpose

    Anti-BTLA [HMBT-6B2], Hamster (Armenian) IgG, kappa

    Specificity

    This antibody is specific for B and T lymphocyte attenuator (BTLA), which functions as a negative regulator of T cell activation and proliferation, and attenuates B cell proliferation upon associating with its known ligand, herpes virus entry mediator (HVEM).

    Characteristics

    Original Species of Ab: Hamster, Armenian

    Original Format of Ab: IgG

    Purification

    Protein A affinity purified

    Immunogen

    This antibody was raised by immunising Armenian hamsters with mouse BTLA:Fc fusion protein.

    Isotype

    IgG kappa
  • Application Notes

    This antibody has been used in immunoblot analyses to confirm that B and T lymphocyte attenuator (BTLA) regulates T cell activation through interaction with herpesvirus entry mediator (HVEM) (Sedy et al, 2005), as well as in FACS and yeast display technology to demonstrate that BTLA exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T Cells (Hurchla et al, 2005). In a mouse conjunctivitis model, treatment with this antibody during the induction phase has been shown to decrease B-cell population, upregulate Th2 cytokine production and increase the conjunctival eosinophile numbers (Ishida et al, 2012). However, treatment with this antibody during the effector phase does not affect the development of experimental conjunctivitis (Ishida et al, 2012).

    Comment

    This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.

    Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    PBS with 0.02 % Proclin 300.

    Preservative

    ProClin

    Precaution of Use

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target

    BTLA (B and T Lymphocyte Associated (BTLA))

    Alternative Name

    BTLA

    Background

    CD272, B and T lymphocyte attenuator, B- and T-lymphocyte attenuator, B and T lymphocyte associated protein, B- and T-lymphocyte-associated protein, BTLA1, FLJ16065, MGC129743

    UniProt

    Q7TSA3

    Pathways

    Cancer Immune Checkpoints
You are here:
Chat with us!